Synonym: (4Z)-rel-; 4(Z)-6-(2-o-chlorophenyl-4-o-hydroxyphenyl-1,3-dioxan-cis-5-yl) hexenoic acid; 4-Hexenoic acid; 6-[(2R,4R,5S)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]-
CAS Number: 117621-64-4
Empirical Formula (Hill Notation): C22H23ClO5
Molecular Weight: 402.87
MDL Number: MFCD00673936
Linear Formula: C22H23ClO5
Product Type: Chemical
| assay |
≥98% (HPLC) |
| color |
white to tan |
| form |
powder |
| InChI |
1S/C22H23ClO5/c23-18-11-6-4-9-16(18)22-27-14-15(8-2-1-3-13-20(25)26)21(28-22)17-10-5-7-12-19(17)24/h1-2,4-7,9-12,15,21-22,24H,3,8,13-14H2,(H,25,26)/b2-1-/t15-,21+,22+/m0/s1 |
| InChI key |
WHUIENZXNGAHQI-YGPRPMEGSA-N |
| originator |
AstraZeneca |
| Quality Level |
100  |
| SMILES string |
OC(=O)CCC=C/C[C@H]1CO[C@H](O[C@H]1c2ccccc2O)c3ccccc3Cl |
| solubility |
DMSO: ≥20 mg/mL |
| storage temp. |
−20°C |
| Biochem/physiol Actions: |
ICI 192605 is a potent thromboxane A2 receptor antagonist. It inhibits platelet aggregation and can reverse the effects of vasoconstrictors such as TXA2 or PGD2. ICI 192605 can reverse vasoconstriction induced by inhibition of NO production by L-NEMA, which leads to an increase in TXA2 release. |
| Features and Benefits: |
This compound is featured on the Prostanoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: |
This compound was developed by AstraZeneca . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: |
5, 25 mg in glass bottle |
| Symbol |
  GHS07,GHS09 |
| Signal word |
Warning |
| Hazard statements |
H302 - H410 |
| Precautionary statements |
P273 - P501 |
| Hazard Codes |
Xn,N |
| Risk Statements |
22-50/53 |
| Safety Statements |
60-61 |
| RIDADR |
UN 3077 9 / PGIII |
| WGK Germany |
WGK 3 |
| Flash Point(F) |
Not applicable |
| Flash Point(C) |
Not applicable |
| Purity |
≥98% (HPLC) |
| Storage Temp. |
−20°C |
| UNSPSC |
12352200 |
